Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Purple Biotech Ltd. Sponsored ADR PPBT

Healthcare  —  Biotechnology
1.49 0.01 0.68% as of 25 Sep
Market cap
$2.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Purple Biotech Ltd. Sponsored ADR (PPBT) Business Profile

Updated before January 2025

Company Overview

Purple Biotech Ltd. Sponsored ADR (PPBT) is a clinical-stage biopharmaceutical company dedicated to the development of innovative cancer therapies. Founded in 2000 and headquartered in Rehovot, Israel, the company has established itself as a leader in oncology research, focusing on the development of first-in-class therapies that target the tumor microenvironment. Purple Biotech is publicly traded on the NASDAQ under the ticker symbol PPBT. The company is led by a team of seasoned executives and researchers, including its CEO, Isaac Israel, who has extensive experience in the biotechnology and pharmaceutical industries. The leadership team is supported by a board of directors with deep expertise in healthcare, finance, and corporate governance.

Core Business Segments

Purple Biotech operates primarily in the oncology sector, with a focus on developing therapies that address unmet medical needs. The company’s core business segments include:

1. Oncology Therapeutics

Purple Biotech’s flagship product candidates are designed to improve the efficacy of existing cancer treatments by targeting the tumor microenvironment. Key products include:

  • CM24: A monoclonal antibody that targets CEACAM1, a protein involved in immune suppression within the tumor microenvironment. CM24 is currently in clinical trials for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.
  • NT219: A small molecule designed to overcome resistance to cancer therapies by targeting IRS1/2 and STAT3 signaling pathways. NT219 is being evaluated in combination with other therapies for the treatment of solid tumors.

2. Research and Development (R&D)

Purple Biotech invests heavily in R&D to discover and develop novel therapeutic candidates. The company collaborates with leading academic institutions and research organizations to advance its pipeline of oncology products.

3. Licensing and Partnerships

In addition to its in-house development efforts, Purple Biotech engages in strategic partnerships and licensing agreements to expand its product portfolio and accelerate the commercialization of its therapies.

Business Model

Purple Biotech’s business model is centered on the development and commercialization of innovative cancer therapies. The company generates revenue through:

  • Licensing Agreements: Partnering with pharmaceutical companies to license its proprietary technologies and product candidates.
  • Collaborative Research: Engaging in joint research initiatives with academic institutions and industry partners.
  • Future Product Sales: Once its therapies receive regulatory approval, Purple Biotech plans to generate revenue through the sale of its products in global markets.

The company’s approach integrates cutting-edge science with a commitment to addressing the needs of cancer patients worldwide. By focusing on the tumor microenvironment, Purple Biotech aims to enhance the effectiveness of existing treatments and improve patient outcomes.

Strategic Direction

Purple Biotech is committed to advancing its pipeline of oncology therapies and achieving long-term growth. Key strategic priorities include:

  • Pipeline Expansion: The company is actively exploring new therapeutic targets and indications to expand its product portfolio.
  • Global Market Penetration: Purple Biotech aims to establish a strong presence in key markets, including the United States, Europe, and Asia.
  • Sustainability Goals: The company is dedicated to conducting its operations in an environmentally and socially responsible manner, with a focus on reducing its carbon footprint and promoting diversity and inclusion.
  • Innovation: Purple Biotech continues to invest in cutting-edge research and technology to maintain its competitive edge in the oncology sector.

Competitive Landscape

Purple Biotech operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A global leader in oncology, known for its immunotherapy products such as Opdivo and Yervoy.
  • Merck & Co.: Another major player in the oncology space, with its blockbuster drug Keytruda.
  • Smaller Biotech Firms: Companies like Arcus Biosciences and Iovance Biotherapeutics, which are also focused on innovative cancer therapies.

Despite the competitive landscape, Purple Biotech differentiates itself through its focus on the tumor microenvironment and its robust pipeline of first-in-class therapies.

Risk Factors

Like any biopharmaceutical company, Purple Biotech faces several risks, including:

  • Regulatory Risks: The company’s product candidates must undergo rigorous clinical trials and regulatory review before they can be commercialized.
  • Market Dependence: Purple Biotech’s success is heavily dependent on the approval and adoption of its therapies.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, which could pose risks to its operations.
  • Financial Risks: As a clinical-stage company, Purple Biotech has yet to generate significant revenue and may require additional funding to support its operations.

Recent Developments

Purple Biotech has made significant progress in advancing its pipeline and strengthening its position in the oncology sector. Recent developments include:

  • Clinical Trials: The company has initiated Phase 1/2 clinical trials for CM24 and NT219, with promising preliminary results.
  • Partnerships: Purple Biotech has entered into strategic collaborations with leading academic institutions to accelerate the development of its therapies.
  • Corporate Strategy: The company has implemented cost-saving measures and streamlined its operations to enhance efficiency and focus on its core priorities.

Investment Considerations

Investors considering Purple Biotech should weigh the following factors:

Strengths

  • Innovative Pipeline: The company’s focus on the tumor microenvironment sets it apart from competitors.
  • Experienced Leadership: Purple Biotech is led by a team of seasoned executives with a proven track record in the biotech industry.
  • Strategic Partnerships: Collaborations with academic institutions and industry partners enhance the company’s R&D capabilities.

Risks

  • Clinical and Regulatory Uncertainty: The success of Purple Biotech’s product candidates is not guaranteed.
  • Financial Challenges: The company may require additional funding to support its operations and advance its pipeline.
  • Market Competition: Purple Biotech faces intense competition from established players and emerging biotech firms.

Conclusion

Purple Biotech Ltd. Sponsored ADR (PPBT) is a promising clinical-stage biopharmaceutical company with a strong focus on oncology. By targeting the tumor microenvironment, the company aims to improve the efficacy of existing cancer treatments and address unmet medical needs. While Purple Biotech faces several risks, its innovative pipeline, experienced leadership, and strategic partnerships position it for long-term growth. As the company continues to advance its therapies through clinical trials and expand its global presence, it remains an attractive investment opportunity for those seeking exposure to the biotech sector.